[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Juin-Hong Cherng\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":80},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644642","far-infrared-therapy-for-the-effect-of-alzheimer-disease-dementia-100644642",false,"NCT07672171","Far-Infrared Therapy for the Effect of Alzheimer Disease Dementia","To Explore the Effect of Far Infrared Therapy on Cognitive Function of Patients With Dementia","Inclusion Criteria:\n\n1. Diagnosed with Alzheimer's disease dementia.\n2. Mini-Mental State Examination (MMSE) score between 18 and 24 (inclusive).\n3. Currently prescribed and maintained on a stable regimen of anti-dementia medication.\n4. No sensory deficits or impairment regarding skin temperature perception.\n5. Patient or a Legally Authorized Representative (LAR) must be willing and capable of providing written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n1. Non-Alzheimer's disease dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia).\n2. Known hypersensitivity to heat or light, including the current use of photosensitizing medications.\n3. Diminished thermal or heat sensitivity, such as from the concurrent use of analgesics, sedatives, or consumption of alcoholic beverages.\n4. Acute injury or acute localized inflammation, including active inflammation, infection, or ulcerated wounds.\n5. Concomitant acute venous thrombosis, varicose veins, severe peripheral arterial occlusive disease (Stage III or IV), lymphatic disease, acute rheumatoid arthritis, acute gout, or active fever.\n6. Presence of mottled erythema or other abnormal dermatological conditions on the scalp or neck.\n7. Localized skin lesions, damage, or open wounds at the device contact sites.\n8. Concurrent participation in any other clinical trial.\n9. Any other underlying pathological conditions or clinical statuses that, based on medical consensus, would preclude safe participation in the study.\n10. Failure or refusal to provide signed informed consent.\n11. Inability or unwillingness to comply with the trial protocols, schedules, or required follow-up evaluations.\n12. History or presence of hemorrhagic disorders or bleeding-related diseases.","ALL","61 Years","92 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Alzheimer's disease (AD), the most common cause of dementia, is a progressive neurodegenerative disorder characterized by cognitive decline, including impaired learning ability, memory loss, and behavioral disturbances.\n\nAccording to surveys conducted by the Ministry of Health and Welfare in Taiwan, the prevalence of dementia among individuals aged 65 years and older was estimated at 7.86% in 2018, affecting more than 280,000 individuals, and is projected to approach 900,000 by 2065, resulting in substantial medical, social, and economic burdens. Current pharmacological treatments provide only limited symptomatic benefits and may be associated with adverse effects. Therefore, safe and effective non-pharmacological interventions that may support cognitive function and reduce caregiver burden are urgently needed.\n\nExperimental studies suggest that far-infrared (FIR) irradiation may enhance mitochondrial oxidative phosphorylation, increase ATP production, and promote microglial amyloid-β clearance, which may help delay the progression of Alzheimer's disease.\n\nThis trial aims to investigate the safety and effects of far-infrared (FIR) therapy on cognitive function in patients with Alzheimer's disease.\n\nThe findings may support the clinical application of FIR therapy as a non-pharmacological intervention to improve cognitive function and quality of life, reduce medication burden and treatment-related side effects, lessen caregiver burden, delay institutionalization, and reduce the social and economic burden associated with Alzheimer's disease.",[27,28],"Dementia","Alzheimer Disease",[30,27,31],"Far-infrared therapy","Alzheimer disease","RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-26","ACTUAL",{"date":38,"type":36},"2022-10-15",{"date":40,"type":21},"2029-10-31",{"name":42,"class":43},"Juin-Hong Cherng","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":5},"100644098","safety-and-efficacy-clinical-trial-of-the-vessel-x-bone-filling-container-system-100644098","NCT07665424","Safety and Efficacy Clinical Trial of the Vessel-X® Bone Filling Container System","The Clinical Investigation to Evaluate the Safety and Efficacy of Vessel-X® Bone Filling Container System","CMT-VX","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be eligible for enrollment in this study:\n\n1. Male or female subjects aged ≥40 and ≤95 years.\n2. Subjects admitted with vertebral compression fractures (VCFs) caused by osteoporosis or trauma.\n3. Surgical site within the range of T6 to L5.\n4. Subjects with normal vital signs and hepatic and renal function values within 1.5 times the upper limit of normal (ULN), as determined by the investigator to be suitable for study participation.\n5. Subjects willing to comply with the study schedule and all required assessment procedures.\n6. Subjects who are conscious, cognitively intact, and able to provide written informed consent.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded from participation in this study:\n\n1. Pathological fractures caused by bone diseases, including benign or malignant tumors, tuberculosis, osteomyelitis, endocrine or metabolic bone disorders, or severe degenerative bone diseases.\n2. Active or severe systemic infections.\n3. Metabolic disorders (e.g., calcium metabolism disorders), immune system disorders, substance abuse, or alcoholism.\n4. Severe primary diseases involving the hematopoietic or endocrine systems, or psychiatric disorders.\n5. History of allergy to implant materials, hypersensitivity reactions, or allergies to multiple medications.\n6. Non-viable bone surrounding the surgical site or insufficient bone quality to support the implant.\n7. Active infection at or adjacent to the surgical site.\n8. Acute spinal instability.\n9. Unwillingness or inability to restrict physical activity or comply with medical instructions.\n10. Considered unsuitable for study participation by the investigator, or unable to provide independent informed consent.","40 Years","95 Years",{"count":56,"type":21},146,[24],"Osteoporotic vertebral compression fractures (OVCFs) are a common and serious complication of osteoporosis, particularly among elderly and postmenopausal patients. OVCFs may result in severe pain, functional impairment, spinal deformity, and reduced quality of life. Conventional conservative treatments, including bed rest, analgesics, and bracing, may provide limited symptom relief. Minimally invasive vertebral augmentation procedures, such as vertebroplasty and kyphoplasty, have been widely used to improve clinical outcomes; however, risks including bone cement leakage and incomplete vertebral restoration remain concerns.\n\nThe Vessel-X® Bone Filling Container System, manufactured by Central Medical Technologies Inc. (CMT), is a third-generation vesselplasty technology designed for percutaneous vertebral augmentation procedures. The system utilizes an implantable biocompatible polyethylene terephthalate (PET) container with a microporous structure for controlled bone cement delivery. The implant remains within the vertebral body after cement injection and is designed to reduce cement leakage while maintaining vertebral height restoration and pain relief.\n\nThis post-market clinical study evaluates the safety and clinical effectiveness of the Vessel-X® Bone Filling Container System at two medical centers in Taiwan with a total target enrollment of 146 subjects:\n\nTri-Service General Hospital (TSGH): 86 subjects randomized in a 1:1 ratio to the experimental and control groups.\n\nTaoyuan General Hospital, Ministry of Health and Welfare (TYGH): 60 subjects randomized in a 1:1 ratio to the experimental and control groups.\n\nThe primary objective is to evaluate the safety of the device by assessing the incidence of unanticipated serious adverse device effects (USADEs). Secondary objectives include evaluation of pain reduction measured by the Visual Analogue Scale (VAS), functional recovery assessed by the Oswestry Disability Index (ODI), and radiographic outcomes including vertebral height restoration and kyphotic deformity correction.",[60,61],"Osteoporosis","Osteoporotic Vertebral Compression Fractures",[63,64,65,66,67,68,69,70,71],"Oswestry Disability Index","Visual Analogue Scale","Serious Adverse Device Effect","Last Observation Carry Forward","CMT Vessel-X® Bone Filling Container System","Vesselplasty","Kyphoplasty","Vertebroplasty","Osteoporotic vertebral compression fractures (OVCFs)","2026-06-22",{"date":74,"type":36},"2026-06-24",{"date":76,"type":36},"2021-04-20",{"date":78,"type":21},"2026-12-31",{"name":42,"class":43},""]